Genomic Biomarkers Market worth $50.31 billion by 2030
The report "Genomic Biomarkers Market by Product & Service (Consumable, Software), Type (Safety, Efficacy), Technology (NGS, PCR), Disease (Cancer, Infectious) -Forecast to 2030" is projected to grow from USD 29.00 billion in 2025 and to reach 50.31 billion by 2030, at a Compound Annual Growth Rate (CAGR) of 11.6% during the forecast period.
Browse 708 market data Tables and 56 Figures spread through 506 Pages and in-depth TOC on "Genomic Biomarkers Market by Product & Service (Consumable, Software), Type (Safety, Efficacy), Technology (NGS, PCR), Disease (Cancer, Infectious) -Forecast to 2030"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/genomic-biomarkers-market-48860286.html
The genomic biomarkers market is experiencing growth, driven by several key factors, including the increasing use of genomic testing in oncology, rare diseases, and inherited disorders, and rapid advancements in PCR and NGS technologies.
The next-generation sequencing (NGS) segment accounted for the largest share of the genomic biomarkers market, by Technology, in 2024.
Next-generation sequencing (NGS) accounted for the largest share of the genomic biomarkers market in 2024. Hospitals, cancer centers, and pharma companies increasingly prefer NGS because a single run can analyze hundreds of genes and complex signatures, making it ideal for comprehensive tumor profiling and the discovery of new prognostic and predictive biomarkers.
In 2024, the pharmaceutical & biotechnology companies segment was the fastest-growing segment, by application.
Pharmaceutical & biotechnology companies were the fastest-growing segment of the genomic biomarkers market by end users. These organizations rely on genomic biomarkers throughout the entire drug development lifecycle, from target discovery and patient stratification to response monitoring and companion diagnostic development, generating the highest and most consistent testing volume.
North America accounted for the largest regional share in the genomic biomarkers market in 2024.
The genomic biomarker market is segmented into North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa. North America holds the highest regional share, reflecting its strong base of academic medical centers, cancer institutes, and commercial labs that have widely adopted NGS-based testing, liquid biopsies, and companion diagnostics. The region also benefits from favorable reimbursement, major government initiatives such as the Cancer Moonshot, and intensive pharma and biotech investment in biomarker-driven clinical trials, all of which reinforce North America’s leading position in genomic biomarker revenues.
Key players in the genomic biomarkers market include Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Illumina, Inc. (US), QIAGEN (Germany/Netherlands), Bio-Rad Laboratories, Inc. (US), Agilent Technologies, Inc. (US), Eurofins Scientific (Luxembourg), Quanterix (US)
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Visit Our Website: https://www.marketsandmarkets.com/
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Genomic Biomarkers Market
- What will your New Revenue Sources be?
- Who will be your Top Customer; what will make them switch?
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
